← Back to Screener
DBV Technologies S.A. (DBVT)
Price$21.00
Favorite Metrics
Price vs S&P 500 (26W)30.37%
Price vs S&P 500 (4W)-2.90%
Market Capitalization$1.01B
All Metrics
Book Value / Share (Quarterly)$0.72
P/TBV (Annual)4.62x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.18%
Cash Flow / Share (Quarterly)$-0.51
Price vs S&P 500 (YTD)3.85%
Gross Margin (TTM)93.12%
Net Profit Margin (TTM)-2611.00%
EPS (TTM)$-1.07
10-Day Avg Trading Volume0.94M
EPS Excl Extra (TTM)$-1.07
Revenue Growth (5Y)-12.95%
EPS (Annual)$-1.05
ROI (Annual)-83.94%
Gross Margin (Annual)86.43%
Net Profit Margin (5Y Avg)-1904.48%
Cash / Share (Quarterly)$0.82
Revenue Growth QoQ (YoY)115.98%
ROA (Last FY)-63.05%
Revenue Growth TTM (YoY)35.77%
EBITD / Share (TTM)$-0.97
ROE (5Y Avg)-140.82%
Operating Margin (TTM)-2606.65%
Cash Flow / Share (Annual)$-0.51
P/B Ratio7.03x
P/B Ratio (Quarterly)4.62x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)177.20x
Net Interest Coverage (TTM)-581.44x
ROA (TTM)-78.14%
EPS Incl Extra (Annual)$-1.05
Current Ratio (Annual)3.67x
Quick Ratio (Quarterly)3.62x
3-Month Avg Trading Volume1.57M
52-Week Price Return147.54%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.72
P/S Ratio (Annual)210.50x
Asset Turnover (Annual)0.02x
52-Week High$4.50
Operating Margin (5Y Avg)-1921.02%
EPS Excl Extra (Annual)$-1.05
CapEx CAGR (5Y)-27.90%
Tangible BV CAGR (5Y)-3.85%
26-Week Price Return39.12%
Quick Ratio (Annual)3.62x
13-Week Price Return17.09%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)3.67x
Enterprise Value$998.726
Revenue / Share Growth (5Y)-27.98%
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)-28.16%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.55x
Pretax Margin (Annual)-2602.29%
Cash / Share (Annual)$0.82
3-Month Return Std Dev71.26%
Gross Margin (5Y Avg)88.12%
Net Income / Employee (TTM)$-1
ROE (Last FY)-87.19%
Net Interest Coverage (Annual)-52.83x
EPS Basic Excl Extra (Annual)$-1.05
Receivables Turnover (TTM)22.36x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-1.07
Receivables Turnover (Annual)5.12x
ROI (TTM)-109.34%
P/S Ratio (TTM)210.50x
Pretax Margin (5Y Avg)-1903.50%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.72
Price vs S&P 500 (52W)112.45%
Year-to-Date Return7.22%
5-Day Price Return0.33%
EPS Normalized (Annual)$-1.05
ROA (5Y Avg)-76.57%
Net Profit Margin (Annual)-2611.00%
Month-to-Date Return-0.03%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-1.02
Operating Margin (Annual)-2606.65%
LT Debt / Equity (Annual)0.59x
ROI (5Y Avg)-120.91%
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-1.07
P/TBV (Quarterly)4.62x
P/B Ratio (Annual)4.62x
Inventory Turnover (TTM)0.83x
Pretax Margin (TTM)-2602.29%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)14.23%
Beta0.45x
Revenue / Share (TTM)$0.04
ROE (TTM)-115.44%
52-Week Low$1.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DBVTDBV Technologies S.A. | 210.50x | 35.77% | 93.12% | — | $21.00 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin, a proprietary patch-based immunotherapy platform that delivers therapeutics through intact skin for immune-mediated disorders. The company's lead program, Viaskin Peanut, targets peanut allergies, with earlier-stage candidates in milk allergy and eosinophilic esophagitis. This epicutaneous delivery approach represents a differentiated mechanism to address significant unmet needs in food allergy treatment.